Large Investment Management Firm Selects FINCAD as its Counterparty Risk Management Solution

Dublin and Vancouver, BC - 10 July 2012

Firm acquires F3 to accurately calculate Credit Value Adjustment

FINCAD, the market leader for innovative over-the-counter (OTC) derivatives solutions, announced today that one of Canada’s largest investment management firms has selected F3 as its counterparty risk management solution. With F3, the Company is now able to accurately calculate Credit Value Adjustment (CVA) for its portfolios.

Prior to F3, the firm used an in-house system of spreadsheets to calculate CVA, but needed a more robust and precise tool to evaluate and manage counterparty credit risk. The Company has selected F3 as its portfolio-level CVA solution to accurately calculate CVA and Potential Future Exposure (PFE) for fixed income, interest rate and credit instruments. The investment management firm plans to expand its use of F3 to include more middle office and valuations users.

Calculating counterparty credit risk is a complex and involved process, requiring sophisticated technology and users. However, F3 significantly reduces the challenges involved in this process and easily provides the investment management firm with reliable and accurate valuations, at a competitive rate.

“Given the current volatility of the financial marketplace, CVA is an increasingly important measure, but implementing a comprehensive, accurate counterparty risk system can be a challenging process,” said Bob Park, CEO and President, FINCAD. “Key challenges to calculating CVA include a lack of flexibility, inconsistent modelling techniques, inability to capture offsetting exposure of netting sets and incorporating and adjusting to changing regulations, such as Basel III. F3 was designed to provide our clients with the flexibility and power to overcome these challenges.”

Become a bobsguide member to access the following

1. Unrestricted access to bobsguide
2. Send a proposal request
3. Insights delivered daily to your inbox
4. Career development